# Anti-MAG First Administration to Human

> **NCT00622609** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 46 (actual)

## Conditions studied

- Cerebrovascular Accident

## Interventions

- **DRUG:** GSK249320A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00622609
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-01
- **Primary completion:** 2009-04-09
- **Final completion:** 2009-04-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622609, "Anti-MAG First Administration to Human". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00622609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*